Intravenous Methylprednisolone use increases the Retention Rate of Abatacept in Rheumatoid Arthritis Patients

Primary tabs

NEWS
Intravenous Methylprednisolone use increases the Retention Rate of Abatacept in Rheumatoid Arthritis Patients

According to the latest study published in the "Rheumatology International" journal, intravenous Methylprednisolone (IVBP) when administered along with Abatacept (ABA) exhibits higher rates of drug retention without additional safety signals and thus help patients with rheumatoid arthritis (RA) to achieve earlier remission.

Haruki Sawada and colleagues conducted a retrospective cohort analysis to evaluate the effect of methylprednisolone in enhancing the retention rates of Abatacept (ABA). A total of 59 patients with RA who got treatment from January 2010 to May 2017 at a single center of Japan were included in the analysis. Forty-seven patients received only ABA and twelve received ABA + IVMP. The ABA + IVMP group received 40 mg IVMP along with first three consecutive ABA doses. Kaplan–Meier analysis was done to determine ABA retention.  The sensitivity analysis was also done by assessing hazard ratios of drug retention rate.

The ABA group showed 72.3%, and ABA + IVMP group showed 91.7% retention rates. No statistical difference was noticed between two groups as per log-rank analysis (p = 0.17).  The hazard ratio of IVMP was found to be 2.9 to 3.7 in three models with no statistical importance according to the results of sensitivity analyses. No patients from the ABA + IVMP group discontinued ABA whereas, seven patients in the ABA group, discontinued the therapy.

Source

Rheumatol Int             

Link:

www.ncbi.nlm.nih.gov/pubmed/30054716

The original title of article:

Concomitant use of intravenous methylprednisolone to increase retention rate of abatacept in rheumatoid arthritis

Authors:

Haruki Sawada et al.

SearchTags: 
Therapeutic, Abatacept, Methylprednisolone, Rheumatoid Arthritis, Joints, Selective Co-stimulation Modulators, Steroids, Retrospective Cohort Study, Efficacy
Log in or register to post comments